PDCD1 and non-small cell lung carcinoma: All patients had disease progression after platinum-based and anti-programmed death 1 (anti-PD1) therapy prior to enrollment, except for two NSCLC patients who were enrolled to receive this treatment after initial platinum-based chemotherapy only.